title: Drug-induced airway diseases.
abstract: Drug-induced airway disease is a significant problem and must be considered in the differential diagnosis. A history of drug intake with a temporal association should raise the physician's suspicion toward a drug-induced cause. Because most of the conditions are amenable to withdrawal of the offending agent, an early diagnosis is essential. Conditions like obliterative bronchiolitis, are usually irreversible, but timely stoppage of the provoking agent can prevent further progression of the disease. Most of the drug reactions are nonallergic and the physician and the patient should be aware of this fact. In view of the constantly-evolving therapies, an active policy to identify and report adverse effects is essential to develop management strategies and treatment recommendations.
authors.affiliation: Mail Point 810, Level D, Centre Block, Southampton General Hospital, Southampton SO16 6YD, UK. ksb@soton.ac.uk
authors.forename: K Suresh
authors.initials: KS
authors.lastname: Babu
authors.forename: Benjamin G
authors.initials: BG
authors.lastname: Marshall
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D016718:Arachidonic Acid / Q000378:metabolism; D001249:Asthma / Q000139:chemically induced* / Q000503:physiopathology; D001986:Bronchial Spasm / Q000139:chemically induced* / Q000503:physiopathology; D001989:Bronchiolitis Obliterans / Q000139:chemically induced / Q000503:physiopathology; D003371:Cough / Q000139:chemically induced / Q000503:physiopathology; D006801:Humans; D007049:Iatrogenic Disease; D008168:Lung / Q000187:drug effects; D009784:Occupational Diseases / Q000139:chemically induced
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D016718:Arachidonic Acid